Colourised scanning electron micrograph of a cell (pink) heavily infected with SARS-CoV-2 virus particles (teal and purple), isolated from a patient sample. Credit: NIAID.

The National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) in the US has initiated an observational study to analyse the short and long-term health outcomes of Covid-19.

The study, called Pediatric Research Immune Network on SARS-CoV-2 and MIS-C (PRISM), will also include multisystem inflammatory syndrome in children (MIS-C).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

NIH noted that Covid-19 usually causes either no illness or only mild illness in children, but some develop serious illness on getting infected and some who initially had no symptoms develop MIS-C later.

A life-threatening condition, MIS-C is marked by severe inflammation of one or more body parts and begins several weeks after SARS-CoV-2 exposure.

Sponsored and funded by the NIAID, the multicentre, observational cohort study will enrol around 250 children and young adults aged 20 or under at around 20 sites in the US.

Participants with detectable SARS-CoV-2 in respiratory samples, with MIS-C symptoms, or both, will be followed for a year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The NIAID Director Anthony Fauci said: “It is critical that we learn how to prevent and treat this rare but very serious syndrome in children.

“Information gathered through the PRISM study may ultimately help clinicians diagnose and treat MIS-C as well as predict which children are susceptible to the disease.”

The study will evaluate the number of children who die, are re-hospitalised, or have major health issues related to Covid-19 at six and 12 months after initial presentation with Covid-19, MIS-C, or both.

Another goal of the study is to analyse the immunologic mechanisms and immune signatures linked with different forms of MIS-C and Covid-19 in children.

The NIH anticipates results from the observational study in mid-2022.

In November, the NIAID announced the commencement of Covid-19 patient enrolment in the fourth iteration of the Adaptive COVID-19 Treatment Trial (ACTT-4).